MX2023013093A - Formas cristalinas de la base libre de (s,e)-4-(dimetilamino)-n-(3 -(4-(2-hidroxi-1-feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il )fenil)but-2-enamida. - Google Patents

Formas cristalinas de la base libre de (s,e)-4-(dimetilamino)-n-(3 -(4-(2-hidroxi-1-feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il )fenil)but-2-enamida.

Info

Publication number
MX2023013093A
MX2023013093A MX2023013093A MX2023013093A MX2023013093A MX 2023013093 A MX2023013093 A MX 2023013093A MX 2023013093 A MX2023013093 A MX 2023013093A MX 2023013093 A MX2023013093 A MX 2023013093A MX 2023013093 A MX2023013093 A MX 2023013093A
Authority
MX
Mexico
Prior art keywords
free base
crystalline forms
phenylfuro
phenylethylamino
enamide
Prior art date
Application number
MX2023013093A
Other languages
English (en)
Spanish (es)
Inventor
Tsu - An HSU
Hsing - Pang HSIEH
Sue - Ming Chang
Original Assignee
Chuan Shih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chuan Shih filed Critical Chuan Shih
Publication of MX2023013093A publication Critical patent/MX2023013093A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2023013093A 2021-07-06 2022-07-06 Formas cristalinas de la base libre de (s,e)-4-(dimetilamino)-n-(3 -(4-(2-hidroxi-1-feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il )fenil)but-2-enamida. MX2023013093A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163218504P 2021-07-06 2021-07-06
PCT/US2022/036260 WO2023283269A1 (en) 2021-07-06 2022-07-06 Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base

Publications (1)

Publication Number Publication Date
MX2023013093A true MX2023013093A (es) 2024-04-09

Family

ID=84802010

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013093A MX2023013093A (es) 2021-07-06 2022-07-06 Formas cristalinas de la base libre de (s,e)-4-(dimetilamino)-n-(3 -(4-(2-hidroxi-1-feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il )fenil)but-2-enamida.

Country Status (12)

Country Link
US (2) US12240858B2 (cg-RX-API-DMAC10.html)
EP (1) EP4330259A4 (cg-RX-API-DMAC10.html)
JP (1) JP7565118B2 (cg-RX-API-DMAC10.html)
KR (1) KR102783648B1 (cg-RX-API-DMAC10.html)
CN (1) CN116916922B (cg-RX-API-DMAC10.html)
AU (1) AU2022307875B2 (cg-RX-API-DMAC10.html)
BR (1) BR112023024853A2 (cg-RX-API-DMAC10.html)
CA (1) CA3217088A1 (cg-RX-API-DMAC10.html)
IL (1) IL308946B2 (cg-RX-API-DMAC10.html)
MX (1) MX2023013093A (cg-RX-API-DMAC10.html)
TW (1) TWI809967B (cg-RX-API-DMAC10.html)
WO (1) WO2023283269A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI906763B (zh) * 2024-02-05 2025-12-01 財團法人國家衛生研究院 表皮生長因子受體抑制劑

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054285A2 (en) * 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
KR101301533B1 (ko) * 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체

Also Published As

Publication number Publication date
TW202309041A (zh) 2023-03-01
IL308946A (en) 2024-01-01
AU2022307875A1 (en) 2023-11-02
CN116916922A (zh) 2023-10-20
IL308946B2 (en) 2026-01-01
JP2024514995A (ja) 2024-04-04
IL308946B1 (en) 2025-09-01
CA3217088A1 (en) 2023-01-12
KR102783648B1 (ko) 2025-03-18
US20230021909A1 (en) 2023-01-26
US20240368175A1 (en) 2024-11-07
WO2023283269A1 (en) 2023-01-12
CN116916922B (zh) 2026-01-02
JP7565118B2 (ja) 2024-10-10
US12240858B2 (en) 2025-03-04
BR112023024853A2 (pt) 2024-02-15
AU2022307875B2 (en) 2024-08-01
KR20230118963A (ko) 2023-08-14
TWI809967B (zh) 2023-07-21
EP4330259A4 (en) 2024-10-09
EP4330259A1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
RU2424240C2 (ru) Антибактериальные производные пиперидина
RU2403247C2 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
JOP20250072A1 (ar) المركبات ثلاثية الحلقات واستخداماتها
ECSP109979A (es) Preparación sólida que contiene alogliptina y clorhidrato de metformina
MX2023006854A (es) Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
CL2019003619A1 (es) Preparación sólida para administración oral.
UY29427A1 (es) Derivados sustituidos de 2,3,4,5- tetrahidro-1h-pirido (4,3-b) indol, composiciones que los contienen, procesos de preparación y aplicaciones
AR038914A1 (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion para fabricar un medicamento
CY1109880T1 (el) ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
HN2002000156A (es) Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
CY1111102T1 (el) 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv
PE20151607A1 (es) Formulaciones de compuestos organicos
AR110249A1 (es) Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo
ECSP099767A (es) Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas
CL2008003639A1 (es) Compuestos derivados de amida; composición farmacéutica que comprende a dicho compuesto; combinación farmacéutica; y uso del compuesto en el tratamiento del vih.
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
CR20240203A (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
MX2025011781A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
BR112023024853A2 (pt) Forma cristalina de (s,e)-4-(dimetilamino)-n-(3-(4-(2-hidroxi-1- base livre de feniletilamino)-6-fenilfuro[2,3-d]pirimidin-5-il)fenil)but-2-enamida (abt-101), composição farmacêutica e método de tratamento de câncer